Samcyprone obtained ODD from the FDA for the treatment of malignant melanoma stage IIB to IV.  Samcyprone is a proprietary topical gel containing the active agent diphenylcyclopropenone (DPCP) and is currently in Phase 2a clinical trials for the treatment of alopecia areata, warts and cutaneous metastases of malignant melanoma according RXi Pharmaceuticals, a biotechnology company headquartered in Marlborough, MA.  Samcyprone works as an immunomodulator by initiating a T-cell response and modifying the expression of multiple genes and miRNAs involved in the immune response to achieve cancer cell killing.  The 5-year survival rate is only about 15% to 20% for stage IV melanoma and in need of new therapeutics.  Currently, DPCP is in clinical trial for treatment of cutaneous metastases of various cancers including melanoma.

 

Related Links:

http://investors.rxipharma.com/file.aspx?IID=4418218&FID=27469217
http://www.rxipharma.com/pipeline/
http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates